AIM ImmunoTech (NYSE:AIM) Stock Price Down 1.9% – What’s Next?

AIM ImmunoTech Inc. (NYSE:AIM)’s share price was down 1.9% during trading on Tuesday . The stock traded as low as $0.13 and last traded at $0.14. Approximately 193,467 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 513,785 shares. The stock had previously closed at $0.14.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price target on shares of AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Tuesday, December 10th.

AIM ImmunoTech Stock Performance

The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05. The stock has a 50-day simple moving average of $0.15 and a 200-day simple moving average of $0.21. The company has a market capitalization of $8.79 million, a price-to-earnings ratio of -0.27 and a beta of 0.41.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).